CyPath Lung demand surges as bioAffinity (BIAF) Q2 2026 test volume more than triples
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Demand for CyPath Lung is increasing, with bioAffinity's test volume for the product more than tripling in the second quarter of 2026. This information is reflected in the company's recent financial filings. The surge in demand appears to be a notable development for bioAffinity, although further details are not specified.